Skip to main content

Spinocerebellar Ataxia Type 1

Neurology
1
Pipeline Programs
5
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Vico Therapeutics
Vico TherapeuticsNetherlands - Leiden
1 program
1
VO659Phase 1/21 trial
Active Trials
NCT05822908Recruiting68Est. Oct 2028
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
All ParticipantsN/A1 trial
Clinical Trial Readiness for SCA1 and SCA3N/A1 trial
Active Trials
NCT01060371Unknown800Est. May 2024
NCT03487367Unknown200Est. Dec 2023
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Clinical Trial Readiness for SCA1 and SCA3N/A
Biogen
BiogenCAMBRIDGE, MA
1 program
Instrumented Data Exchange for Ataxia StudyN/A1 trial
Active Trials
NCT04268147Completed128Est. Jun 2024
Pfizer
PfizerNEW YORK, NY
1 program
Instrumented Data Exchange for Ataxia StudyN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Vico TherapeuticsVO659
BiogenInstrumented Data Exchange for Ataxia Study
Angeles TherapeuticsClinical Trial Readiness for SCA1 and SCA3
Angeles TherapeuticsAll Participants

Clinical Trials (4)

Total enrollment: 1,196 patients across 4 trials

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

Start: Feb 2023Est. completion: Oct 202868 patients
Phase 1/2Recruiting
NCT04268147BiogenInstrumented Data Exchange for Ataxia Study

Instrumented Data Exchange for Ataxia Study

Start: Jun 2019Est. completion: Jun 2024128 patients
N/ACompleted
NCT03487367Angeles TherapeuticsClinical Trial Readiness for SCA1 and SCA3

Clinical Trial Readiness for SCA1 and SCA3

Start: Aug 2018Est. completion: Dec 2023200 patients
N/AUnknown

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Start: Apr 2010Est. completion: May 2024800 patients
N/AUnknown

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,196 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.